Stefan Barta, MD, Oncology, Philadelphia, PA

StefanKlausBartaMDMD, MS, MRCP(UK)

Oncology Philadelphia, PA

Hematologic Oncology

Associate Professor, Leader T-cell Lymphoma Program, University of Pennsylvania

Dr. Barta is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Barta's full profile

Already have an account?

  • Office

    Perelman Center for Advanced Medicine, University of Pennsylvania
    3400 Civic Blvd, PCAM South, 12-177
    Philadelphia, PA 19111
  • Is this information wrong?

Education & Training

  • Albert-Einstein College of Medicine of Yeshiva UniversityMS, Clinical Research Methods, 2009 - 2011
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineFellowship, Hematology/Oncology, 2008 - 2010
  • Mount Sinai St. Luke's - West Hospital Center
    Mount Sinai St. Luke's - West Hospital CenterResidency, Internal Medicine, 2004 - 2007
  • St. Bartholomew’s & Royal London HospitalFellowship, GU Medicine and HIV (ID subspecialty), 2003 - 2004
  • St. Bartholomew’s & Royal London Hospital School of MedicineResidency, 2001 - 2003
  • Burnley General HospitalInternship, 2000 - 2001
  • Whittington HospitalResidency, 2001
  • Whipps Cross HospitalInternship, 1999 - 2000
  • Goethe University Frankfurt Medical Faculty
    Goethe University Frankfurt Medical FacultyClass of 1999

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2014 - 2022
  • NY State Medical License
    NY State Medical License 2010 - 2016
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Distinction for Clinical Research 12th Annual ECOG-ACRIN Young Investigator Symposium, 2012
  • Young Investigator American Society of Clinical Oncology, 2010
  • Outstanding Senior Resident St. Luke’s Roosevelt Hospital, New York, USA, 2007

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib  
    Stefan Barta, MD, Clinical Pharmacokinetics
  • Synergy of Sequential Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti- CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine M...  
    Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A, Leukemia & Lymphoma 2012 Oct; 53(10):1999-2003
  • A phase I study of a combination of anti-CD19 and anti- CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.  
    Schindler J, Gajavelli S, Ravandi F, Shen YM, Parekh S, Braunschweig I, Barta S, Ghetie V, Vitetta E, Verma A, Br J Haematol 2011;154:471-6. PMID 21732928
  • Join now to see all

Abstracts/Posters

  • Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
    Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
    Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
    Stefan K. Barta, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinica... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Identification of Prognostic Markers Remains ‘Holy Grail’ in Follicular Lymphoma Research
    Identification of Prognostic Markers Remains ‘Holy Grail’ in Follicular Lymphoma ResearchJuly 17, 2019 22:36
  • Outcomes with AHCT Consolidation in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era
    Outcomes with AHCT Consolidation in Younger Patients with Mantle Cell Lymphoma in the Rituximab EraFebruary 26, 2019 17:35
  • Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin Lymphoma
    Combination Immunotherapy Shows High Activity Against Recurrent Hodgkin LymphomaDecember 04, 2018 17:51
  • Join now to see all

Professional Memberships